Inside cancer, from a simple blood draw
24/04/2026
Written by Edmond Kwan MBBS PhD FRACP Genitourinary Cancer Medical Oncologist, Eastern Health Senior Research Fellow & Lab Head, Monash University Cancer isn’t one disease.
0
Trials
0
+
Sites
0
+
Patients Enrolled
0
Countries
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need,
collaborates with the leading clinicians and researchers in below the
belt cancers, and communicate frequently and effectively with the
broader community along the way.
Join ANZUP
If you are not yet an ANZUP member then join our large multidisciplinary network of urogenital and prostate cancer researchers, clinicians, nurses, psychologists, scientists, allied health and consumer representatives. Membership is free.
If you are a member of the community and would like to learn more about below the belt cancers, then join ‘Friends of ANZUP’.
Trials and Research
All of the major milestones in controlling cancer worldwide have come through clinical trials, but we still have a long way to go to help every person affected, at risk or diagnosed with this disease.
We have clinical trials across each cancer type, in various stages of progress: in activation, open to patient recruitment, in follow up and completed trials.
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
🔎 Today at #ASCO26, @ChrisSweens1 presented new evidence from the #ENZAMET study that showed that high Decipher Prostate Genomic Classifier scores can predict OS benefit of the addition of docetaxel to androgen deprivation therapy plus enzalutamide for patients with mHSPC:
Assessment of the ability of #Decipher #Prostate genomic classifier >0.85 to identify patients who benefit from adding docetaxel to ADT + enzalutamide: Level 1B evidence from the #ENZAMET study. Presentation by @ChrisSweens1 @UniofAdelaide. #ASCO26 written coverage by @RKSayyid
Decipher is consistent across trials in IDing group benefiting from intensification. @ChrisSweens1 presents data from ENZAMET - great collab btw @Decipher_VCYT @ANZUPtrials and participating centers. More molecular data coming from ENZAMET - see our germline profiling poster tmrw
Latest News
Inside cancer, from a simple blood draw
24/04/2026
Written by Edmond Kwan MBBS PhD FRACP Genitourinary Cancer Medical Oncologist, Eastern Health Senior Research Fellow & Lab Head, Monash University Cancer isn’t one disease.